TScan Therapeutics plans to initiate its first Phase 3 trial in the second quarter of 2026 for TSC-101 to prevent relapse after allogeneic hematopoietic cell transplantation in hematologic malignancies. The company also completed enrollment of Cohort C in its Phase 1 ALLOHA study using a commercial-ready manufacturing process and secured FDA clearance for two additional INDs, TSC-102-A01 and TSC-102-A03, which target CD45 in HLA-A•01:01– and HLA-A•03:01–positive patients, respectively. With $152.4 million in cash and cash equivalents, TScan projects a runway into the second half of 2027 and expects to share initial Cohort C data in the second quarter.
The strategic thrust is clear: move TCR-T from rescue therapy to relapse prevention and make manufacturing readiness a front-line priority. If successful, this would reposition donor-derived, HLA-restricted TCR-T as a one-time, post-transplant intervention competing with maintenance drugs, donor lymphocyte infusions, and emerging bispecifics. The central question is whether clinical signal, operational feasibility, and payer economics can align fast enough to turn a niche, logistics-heavy modality into a standard adjunct to transplant care.
Early signs are encouraging but remain underpowered. Updated Phase 1 data presented at ASH 2025 showed TSC-101 was well-tolerated with no dose-limiting toxicities and trended toward improved relapse-free and overall survival, with all evaluable TSC-101 recipients at two years remaining relapse-free versus one in four controls. The Cohort C readout, produced with a commercial-ready process, will be closely watched for consistency and scalability—often the fault line where cell therapies stumble between academic feasibility and multicenter reproducibility. Launching a pivotal study immediately thereafter suggests a defined regulatory path and endpoints suited to post-transplant risk reduction, likely centered on relapse-free survival and clinically meaningful reductions in post-acute interventions.
The CD45-targeted INDs expand the addressable market by covering two common HLA subtypes, yet they also underscore the segmentation inherent to HLA-restricted TCRs. Routine HLA typing in the transplant setting lowers the barrier to identification, but aligning patient HLA status, donor compatibility, and manufacturing slots introduces real-world friction that Commercial and Medical Affairs teams must solve. Hospital contracting, care pathway mapping, and center enablement will be as determinative as the label. Payers will demand a clear cost-offset story versus maintenance therapies and reinterventions, supported by rigorous real-world outcomes across graft-versus-host risk, infections, rehospitalizations, and steroid exposure.
Financially, TScan increased 2025 revenue to $10.3 million, largely from collaboration activity, managed R&D at $114.2 million, and reported a net loss of $129.8 million. The discontinuation of its solid tumor PLEXI-T trial and pivot toward in vivo engineering aligns with a broader industry recalibration: focus on hematologic indications with cleaner antigen biology while investing in next-wave in vivo approaches that may compress cost and complexity. For competitors in TCR and cell therapy, the move spotlights a practical path to value creation in post-transplant care, where endpoints are faster, biology is tractable, and center concentration accelerates adoption—if logistics are mastered.
The next two quarters set the trajectory. Cohort C durability, manufacturing reproducibility, and the design of the pivotal trial will determine regulatory momentum and payer readiness. If TScan can convert early signals into a registrational package and a center-friendly operational model, post-transplant TCR-T could claim a defensible foothold. If HLA logistics, marginal effect sizes, or CMC execution falter, the category risks remaining a promising but peripheral option. The decisive test now is whether relapse prevention can become cell therapy’s next scalable franchise rather than its next bespoke exception.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
